IFITM1 has been shown to be overexpressed in several types of cancers, including colorectal, gastrointestinal, head and neck, and breast cancers, and its overexpression positively correlates with tumor progression and increased invasiveness [14, 18–21]. Here, IFITM1 is linked to neoplasm.